ADTX aditxt.com: מקדם חוב לטווח ארוך להון

Aditxt (ADTX) is pioneering the development of immunity analysis and correction systems, establishing authority through precision personalized therapy methods. The team leverages the expertise of leading IT specialists and biologists, who are retained via stock option programs. However, debt burdens and a capital shortfall are hindering the launch of patented software. This price chart reflects the 0.00 metric, confirming the risks of eroding competitive advantages due to a lack of capital.

Investors must evaluate the stability of an asset's financing structure to determine bankruptcy risks. This ratio compares liabilities with maturities exceeding one year to net equity, measuring the degree of debt leverage. By analyzing the long-term debt-to-equity profile, one can track the balance between borrowed and owned capital. This is critical for Aditxt (ADTX), as the lack of operating profit makes the company dependent on external financing. The ability to raise capital without excessive leverage determines the viability of its medical developments.